CoChat

Clinical trial: the glucagon‐like peptide‐1 analogue ROSE‐010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo‐controlled, double‐blind study

HELLSTRÖM, P. M., HEIN, J., BYTZER, P., BJÖRNSSÖN, E., KRISTENSEN, J., SCHAMBYE, H. · 2009 · Alimentary Pharmacology & Therapeutics
Cited by 91

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Summary: Background There is currently no treatment available to manage acute pain attacks in IBS patients regardless of subtype. Aims To evaluate efficacy and safety of the GLP‐1 analogue ROSE‐010 in patients with irritable bowel syndrome (IBS) through a randomized, double‐blind, placebo‐controlled study. Methods Eligible patients (n = 166) meeting Rome II criteria were randomly assigned to receive single subcutaneous injections of ROSE‐010 100 μg, 300 μg and placebo in a cross‐over design. Safety was assessed from spontaneously reported adverse events and measurement of vital signs. Patient‐rated pain relief and intensity were measured on a 100‐mm visual analogue scale. The primary efficacy variable was proportion of patients with >50% maximum total pain relief response from 10 to 60 min after treatment. Secondary endpoints included the maximum summed pain intensity difference, time to meaningful pain relief and patient ratings of satisfaction with treatment. Results Twice as many patients were responders in the primary efficacy endpoint after both ROSE‐010 injections compared to placebo (24%P = 0.011, 23%P = 0.005, and 12% after 300 μg, 100 μg and placebo injections, respectively). Similar results were obtained for the proportion of patients with total pain intensity response. Times to meaningful and total pain relief were shorter for both doses of ROSE‐010 compared with placebo. Compared with placebo, more patients (P < 0.05) were satisfied with ROSE‐010 and considered ROSE‐010 better than previous IBS medications used. Conclusion ROSE‐010 was well tolerated and provided fast and effective relief of acute pain attacks on demand in IBS patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2008.03870.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Cited by

See all 91

Metadata

Authors
HELLSTRÖM, P. M., HEIN, J., BYTZER, P., BJÖRNSSÖN, E., KRISTENSEN, J., & SCHAMBYE, H.
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2008-12-16
Volume
29
Issue
2
Pages
198-206
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W1964357386
Cited by
91
References
12
FWCI
4.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical trial: the glucagon‐like peptide‐1 analogue ROSE‐010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo‐controlled, double‐blind study. https://app.cochat.ai/papers/10.1111/j.1365-2036.2008.03870.x
The paper
HELLSTRÖM, P. M., HEIN, J., BYTZER, P., BJÖRNSSÖN, E., KRISTENSEN, J., & SCHAMBYE, H. (2009). Clinical trial: the glucagon‐like peptide‐1 analogue ROSE‐010 for management of acute pain in patients with irritable bowel syndrome: a randomized, placebo‐controlled, double‐blind study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.2008.03870.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.